| This exploratory study examined the interplay between R&D strategies, management capabilities and innovation in the biopharmaceutical industry using Ansoff's Success Model as the theoretical frame. It was necessary to develop a best fitting innovative management model biopharmaceutical executives can use to design and execute strategies for higher levels of innovation - a keystone to any pharmaceutical company's success. R&D strategies consisted of collaboration strategy (domestic) and offshore R&D strategy, while management capabilities included openness to networking, openness to new skills and technology, openness to information sharing and strategic aggressiveness.;88 R&D related managers from biopharmaceutical companies in the United States completed a questionnaire developed for this study. Descriptive statistics, correlation, factor analysis, and multiple regression analysis were used to test the study's hypotheses. Main findings uncovered significant relationships between innovation and strategic aggressiveness, openness to networking, openness to new skills and technology, R&D collaboration strategies (domestic) and openness to information sharing. Additionally, results showed that collaboration had a multifaceted relationship with strategic aggressiveness and innovation. Using regression analysis, a best fitting innovation management model was developed where strategic aggressiveness and openness to informal networking were the strongest predictors. This study revealed that R&D strategies and management capabilities were contributors and predictors in achieving innovation in the biopharmaceutical industry. Thus, biopharmaceutical executives and R&D managers are provided additional tools, rooted in practical knowledge, to continue their innovative endeavors.;Keywords: innovation, openness, managerial openness to informal networking, managerial openness to new skills/technologies, managerial openness to online information, strategic aggressiveness, R&D collaboration strategy (domestic, offshore R&D), R&D management capabilities, best-fitting innovation model, regression model, biotechnology, pharmaceutical industry. |
